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Summary Breast cancer screening is generally accepted as an effective means of reducing breast cancer
mortality in post-menopausal women. In this analysis the impact of nationwide screening on clinical medicine
and the effects for the women involved are quantified. Effect estimates are based on results from screening
trials in Utrecht (DOM-project) and Nijmegen, and on bi-annual screening of women aged 50-70.
The consequences for health care are based on generally accepted assessment and treatment policies. The
number of assessment procedures for non-palpable lesions will increase by 12% per year in the build-up
period, and will remain slightly higher. The total number of biopsies in a real population is expected to
decrease. Screening will lead to a shift in primary treatment modalities, as 15% of mastectomies will be
replaced by breast conserving therapy. The temporary increase in the demand for primary treatment in the
first years will be followed by a decrease in the demand for treating women with advanced disease. Favourable
effects outweigh the inevitable unfavourable effects, with high quality screening and an appropriate invitation
system. Breast cancer screening can also be recommended after considering other consequences than mortality
reduction.
Several trials have shown that mammographic screening of
post-menopausal women reduces breast cancer mortality
(Shapiro et al., 1982; Verbeek et al., 1984; Collette et al.,
1984; Tabar et al., 1985; UK Trial 1988; Andersson et al.,
1988). The introduction of a national programme in the
United Kingdom, offering tri-annual screening to women
aged 50-65, would result in a mortality reduction of 8%
(Knox, 1988). In the Netherlands with bi-annual screening of
women aged 50-70, this figure would be 12% (van der Maas
et al., 1989).
Although mortality reduction is the fundamental effect
(Day et al., 1989), there is much debate about other desirable
and undesirable consequences of breast cancer screening
(Warren, 1988; Skrabanek, 1988). However, publications which
quantify these consequences are lacking. Starting to screen
will result in a temporary increase in the number of women
with newly diagnosed breast cancer. Detecting these cancers
at an earlier stage will affect the type of assessment and
treatment. Mass screening will also generate referrals of
women, who appear to have no breast cancer (false positives)
(Forrest, 1986).
This report presents this impact of nationwide screening on
three issues: change in referral patterns and assessment pro-
cedures; change in breast cancer incidence; and change in
stage distribution and subsequent treatment. An overview is
given of favourable and unfavourable effects for the women
involved, and the consequences for health care.
The computations are made for the Dutch population, but
the conclusions are relevant to other countries too. Predic-
tions are made for both the first years of implementing the
programme and the stable situation. Medical activities out-
side the programme are included.
Materials and methods
Generally accepted medicalpractice
A flow chart was made of the different assessment procedures
that are used when breast cancer is suspected. Another flow
chart was made of the main primary therapeutic procedures,
representing generally accepted medical practice in the
Netherlands. The criteria for the choice between available
medical procedures were defined on the basis of protocols of
the Dutch Comprehensive Cancer Centres, on literature and
on interviews with clinicians.
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Assessment and excision biopsy
In assessing breast abnormalities, at least three successive
steps were distinguished: physical examination, clinical
mammography and excision biopsy (with possible specimen
radiography). Additional possibilities which were taken into
account for palpable lesions only were fine needle aspiration
(cytology) and ultrasound.
Estimates of the number and type of these procedures used
in the situation without screening were based on the follow-
ing sources: general practitioners' registry (Trouw, 1986); the
radioactivity and radiation application division of the Minis-
try of Welfare, Health and Cultural Affairs; the Central
Office for the Administration of Specialists' Fees (De Waard
et al., 1986); and the Steering Committee on Future Health
Scenarios (1988).
Estimates on the change in numbers and types of assess-
ment when introducing mass screening were derived using the
referral patterns from the Dutch screening trials (Verbeek et
al., 1984; Collette et al., 1984) in the first 10 years. The
Dutch results were adjusted for the fact that these were
achieved in experimental projects, in which quality standards
will now have reached higher levels than at the beginning of
a nationwide programme. The positive predictive value of a
screening mammogram for women aged 50-70 is estimated
to be 40% for the first screen and 60% for subsequent
screens in the Netherlands. A distinction is also made
between the predictive values for biopsies of non-palpable
and ofpalpable lesions. False positives are assumed not to be
treated.
When implementing screening, a decrease can be expected
in the number of mammograms for women aged 50-70,
resulting from visiting the general practitioner. This decrease
in mammograms and possibly successive assessment is as-
sumed to be proportional to the decline in clinically detected
breast cancers.
Therapy
All women with breast cancer but without signs of distant
metastases are assumed to receive primary treatment
independently of the way it is diagnosed. The type of primary
treatment presently used was determined by analysing data
on hospital admissions and breast surgery in the Netherlands
from 1983 to 1985 (unpublished data), data from clinicians
and treatment protocols.
The following types of treatment with curative intent were
distinguished: total mastectomy (dCIS); total mastectomy
with axillary dissection; total mastectomy with axillary
dissection and postoperative radiotherapy; and breast con-
serving therapy.
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Estimates on future developments were based on expert
interviews, international recommendations and literature
(Steering Committee, 1988; Hayward & Rubens, 1987; Harris
et al., 1985; Holland et al., 1985). This resulted in the
assumption that women with invasive breast carcinoma up to
3 cm in diameter, without fixed axillary lymph nodes, will
undergo breast conserving therapy in the Netherlands.
Women with axillary lymph node metastases are assumed
to receive adjuvant systemic therapy: CMF for premeno-
pausal and Tamoxifen for post-menopausal women (Early
Breast Cancer Trialists' Collaborative Group, 1988). Irradia-
tion on regional lymph nodes is assumed to depend on both
lymph node metastases and tumour size.
Women with distant metastases present at first detection of
breast cancer or diagnosed in the course of time are assumed
to be treated for advanced disease. The policy for this treat-
ment was based on a reported file study of 52 patients with
breast cancer metastases (De Waard et al., 1986).
Simulation model ofmass screening
The simulation package MISCAN was used to predict the
effects of screening (Habbema et al., 1987). The model is
based on the development of invasive breast cancer in three
stages, reflecting its size. Five per cent of the invasive cancers
are assumed to be preceded by a screen-detectable ductal
carcinoma in situ, for which 100% progression is assumed.
Key parameters of the model are the mean duration of
pre-clinical screen-detectable disease, the sensitivity of mam-
mography and the improvement in prognosis for screen-
detected cases. These parameters were derived from results of
the HIP-analysis (Habbema et al., 1986), and from a new
analysis of the results from the first 10 years of the Dutch
trials (van der Maas et al., 1989). Results from the ran-
domised Kopparberg/Ostergotland trial were used for
estimating the improvement in prognosis in screen-detected
patients (Tabar et al., 1985). The risk of dying from other
causes is incorporated into the model.
In this analysis the simulated screening policy consists of
mammography for women aged 50-70, starting in 1988 and
ending in 2015, but effects emerging after 2015 are also
calculated. The screening interval was varied but only results
with a 2-year interval, being the future Dutch policy, will be
presented. The attendance rate was based on the Dutch trials
and assumed to be 70% on average. The build-up period is
considered to last for 7 years.
The model predicts the yearly number of women with
newly diagnosed breast cancer in the situation with screening
and if no screening is carried out. Cancers are classified
according to size, invasiveness and way of detection. The
simulated data were combined with data on lymph node
metastases and on distant metastases from all breast cancer
cases in Utrecht and Nijmegen (screen-detected and clinically
detected). This resulted in predictions on the distribution of
cancers according to size, lymph node metastases and distant
metastases.
By using the assumptions on predictive values, assessment
and treatment flow charts, these epidemiological data were
transferred into outcomes concerning national assessment
and treatment procedures. It is assumed that all women who
died from breast cancer would have been treated for
advanced disease.
Results
Assessmentproceduresfor breast cancer
In the Netherlands, it is the general practitioner who is
consulted first in the case of breast symptoms or complaints.
Dutch registries reveal that in the course of one year 9% of
the female population older than 40 visits the physician for
breast assessment. About 30% of the consulting women are
referred for clinical mammography, which will in turn lead to
an excision biopsy in about one-third of the referrals.
From other sources we have estimated the yearly total
number of clinical mammographies to be about 120,000.
Adjusting this figure for mammograms due to other reasons
(reconstructive surgery, follow-up, metastases of unknown
primary), or in other age groups, each year a mammogram is
made in 2% of the women older than 40 years to confirm or
exclude the possibility of breast cancer. This estimate corres-
ponds well with that from the general practitioners registries.
Table I shows the main steps in the diagnosis and treat-
ment of women with a possible breast cancer in the Nether-
lands, and the predicted numbers either with or without mass
screening.
In 1988 without national screening, 71,000 women were
referred for clinical mammography and 23,500 women suc-
cessively underwent an excision biopsy to exclude or confirm
breast cancer. Related to the annual incidence rate, which
amounted to about 7,300, it can be concluded that the ratio
between the number of diagnosed cancers and the number of
biopsies is rather low. Malignancy is only confirmed in 30%
of these biopsies, thus in 10% of the clinical mammograms.
Table I also shows that the age group 50-70, the target
population of the future Dutch screening programme,
accounts for 43% of all breast cancer cases. Given the
assumptions on screening, in 1994 when the screening net-
work is being completed, a 10% decrease may be expected in
the total number of women referred for clinical mammo-
graphy. The number of women with newly diagnosed breast
cancer is higher, mainly because of the prevalence load of
pre-clinical cancer in the screened population.
In the first years of the programme, the decrease in bi-
opsies is not as evident as the decrease in mammograms. This
is due to prevalence load, to the relatively large number of
non-palpable lesions detected by screening and to a lower
predictive value at the first screen.
Especially in the start-up period, there will be an increase
in the number of biopsies for non-palpable lesions of approx-
imately 12% per year. After this period, the number of
Table I Key data on the diagnosis and treatment of breast cancer
Referralsfor Treatment of
clinical Excision Breast Primary advanced
mammographya biopsiesa cancers treatment diseaseb
1988
No screen, all ages 71,000 23,500 7,300 6,850 2,600
No screen, age 50-70 30,300 (43%) 10,000 (43%) 3,100 (43%) 2,900 (43%) 1,000 (38%)
1994
No screen, all ages 73,500 24,500 7,750 7,250 2,850
With screen, all ages 66,000 23,800 8,750 8,275 2,750
1998
No screen, all ages 77,000 25,500 8,000 7,450 3,050
With screen, all ages 64,500 23,000 8,225 7,700 2,900
Predicted annual numbers for the Netherlands, with and without mass screening. Years 1988, 1994 (network complete) and 1998
(steadysituation). Bi-annual screening ofwomen aged 50-70. Female inhabitants40-84years: 3 million. Fortheyear 1988 numbers are
also given for the 50-70 age group.
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biopsies for non-palpable lesions will remain slightly higher.
On the other hand, a strong decrease of 2,700 biopsies of
palpable lesions per year can be expected in the long run.
The decrease in assessment is explained by the fact that the
positive (mammographic) predictive value of 40-60% in a
screening programme is much higher than the predictive
value of a (diagnostic) referral by general practitioners.
Women with newly diagnosed breast cancer
At the start of screening an initial increase is expected in the
number of women with newly diagnosed breast cancer. In
1994 1,000 (= 13%) extra cases will be diagnosed (Figure 1).
The number of women with breast cancer will remain slightly
higher (3%) in the steady state of screening. The latter is
caused by the (earlier) detection of breast cancer in women
who would have died from other causes (in the absence of
screening), before breast cancer had been diagnosed.
Screen-detected cancers tend to be smaller and tend to
have a more favourable lymph node status than clinically
diagnosed cancers (Figure 2a and b). Figure 2 applies to the
years following the build-up period, when 26% of all women
with breast cancer will be detected through screening.
The programme will also detect some 125 women each
year with ductal carcinoma in situ (dCIS), which represents
1.5% of all newly diagnosed breast cancers. This carcinoma
is diagnosed only occasionally in a clinical setting (Rosen,
1979; Rosner et al., 1980). This change is important to realise
because of the existing uncertainty about the natural history
of dCIS (Schnitt et al., 1988).
Changes in treatment
The total number ofwomen to be treated with curative intent
will increase as a result of screening temporarily. The more
favourable stage distribution will also influence the modality
used, in particular breast conserving therapy. Our analysis of
hospital registries shows a moderate increase in breast con-
serving therapy in the years 1983-1985 (from 9% in 1983 to
12% in 1985). However, in recent years this development has
continued. Considering the present treatment protocols we
have concluded that in the near future approximately 40% of
women with breast cancer will undergo breast conserving
therapy if no screening is carried out.
Figure 3 shows the predicted changes in treatment as a
result of mass screening, compared to the situation without
screening in 1994 (first column). The second column of each
modality applies to the build-up period with a large number
of prevalent cases (1994) and the third column to the steady
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Figure 2 Predicted distribution of two parameters in screen-
detected (K) and in clinically diagnosed (0) breast cancers. The
distribution applies to the stable situation 2000-2015. Screening
women aged 50-70 every 2 years. a, Distribution by size of
tumour. b, Percentage of axillary lymph node metastases by size
of tumour.
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Figure 1 Predicted increase (%) in the yearly number of women
with newly diagnosed breast cancer, when implementing nation-
wide screening. Percentage compared to the situation without
mass screening in that year. Screening 2-yearly, women aged
50-70. Build-up period 1988-1995: 1988, 8% of the screening
network functioning; 1991, 52% of the screening network func-
tioning; 1995, screening network complete.
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Figure 3 Yearly number of primary treatment modalities for
breast cancer and predicted changes as a result of nationwide
screening of women aged 50-70 every 2 years. Build-up period
1988-1995. Demographic change between 1994 and 1998 ex-
cluded. a, Year 1994 without mass screening. b, Year 1994 with
mass screening (network being completed). c, Year 1998 with
mass screening (stable situation). *, total mastectomy; IM,
mastectomy + radiotherapy; U, breast conserving therapy; U,
adjuvant systemic treatment.
state (1998). In the long run the expected increase in breast
conserving therapy will be 25% per year, compared to the
situation without screening. More tumours are detected with
a size under 3 cm and without lymph node metastases.
Consequently, the number of mastectomies (and axillary
dissection) without postoperative radiotherapy will decrease
by 13%. The number of women treated by mastectomy,
axillary dissection and postoperative radiotherapy will
decrease by 17% per year, as a result of the more favourable
lymph node stage. The 8% decrease in adjuvant systemic
treatment also reflects the difference in node involvement.
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In the first years of screening the change in breast conserv-
ing therapy is even 35%, as a result of the more pronounced
increase in newly diagnosed cancers. This may be a relatively
small increase on the total number of surgical procedures,
but it will cause a strong increase for radiotherapy sessions.
At present one-quarter of all new patients who need
radiotherapy are breast cancer patients. On the other hand,
the stage distribution of breast cancers detected at the first
screening round is still less favourable compared to cancers
detected in the stable situation some years after. Therefore, in
the first years of the programme, the number of mastectomies
will only decrease gradually.
Finally, the influence on treatment of advanced disease is
important (Table I). For each patient, this involves a com-
bination of treatments, spread out over a longer period. In
the absence of screening each year 2,600 breast cancer
patients undergo palliative treatment for the first time, due to
diagnosing breast cancer at an advanced stage, or due to
recurrences. Mass screening will reduce the number by 3.5%
in 1994, and by 5% in 1998. By the year 2015 the reduction
amounts to 12%, which is calculated to be the maximum
reduction for the Dutch programme (van der Maas et al.,
1989). It will take 25 years for this change to be reached,
which is quite different from the immediate changes in
primary treatment.
Favourable and unfavourable effectsfor women
Table II summarises predicted favourable and unfavourable
effects of nationwide screening. In terms of quality of life,
some effects seem relatively unimportant for the individual
woman. However, if applied to many women, these could
mean important overall effects. If one million women aged
50-70 are screened at 2-yearly intervals, some 2,100 women
will subsequently undergo an excision biopsy, without breast
cancer being confirmed (false positives). Breast cancer will be
diagnosed in 215 women who would otherwise have died
from other causes before the disease would have become
manifest.
Favourable aspects strongly outweigh the disadvantages. A
total of 840 women will not have to be treated for advanced
disease, which is also the number of breast cancer deaths
prevented. At the same time this represents a large gain in
quality of life in the group of women with breast cancer.
A relative increase in breast conserving therapy of 1,400
(per one million screens) should also be considered as an
Table 11 Favourable and unfavourable effects when implementing
nationwide breast cancer screening of women aged 50-70 every
2 years
Unfavourable ejJects Favourable effects
Invitations 1.45 million Decrease in clinical 35,000
Screens 1.00 million mammograms
Clinical mammograms 7,300 via physicians
Screen false positives 2,100 Decrease in biopsies 7,950
which have led to a outside the
biopsy programme with benign
result
Additional number 215 Total number of 3,850
of breast cancers screen-detected cancers
detecteda (including Decrease in clinically 3,635
dCIS) diagnosed cancers
Mastectomies for dCIS 280 Increase in breast 1,400
conserving therapy
Decrease in 1,050
mastectomy
Decrease in adjuvant 715
systemic treatment
Decrease in treating 840
advanced disease
Life-years after known 14,400 Life-years gained 13,800
diagnosis of Breast cancer deaths 840
breast cancer prevented
Numbers are counted for the period 1988-2088 and standardised per
one million screens. Mass screening 1988-2015 (total of 14.6 million
screens). aOtherwise died from other causes.
asset. Although this is an intensive treatment, the higher
probability of breast conservation might be one of the
reasons for a woman to attend the screening. The decrease in
mastectomies does not equal the increase in breast conserving
therapy, as a result of the higher incidence and the detection
of non-invasive lesions.
The decrease in assessment is also important. There will be
a reduction in the number of biopsies with a benign histo-
logical result outside the programme, much larger than the
increase in false positive biopsies from screen referrals. The
preceding number of clinical mammograms will decrease too,
and may be related to the increase in clinical mammograms
made for screened women.
Finally, not all women will benefit from the early detec-
tion. Table II shows that 13,800 life-years are actually
gained. However, the earlier diagnosis also causes the quality
of 14,400 women-years to be deteriorated by knowing the
diagnosis breast cancer.
Discussion
The estimates about the impact on clinical medicine are
calculated for the Dutch population and screening policy. A
relevant question is whether the results would also apply to
other countries where centrally organised programmes are
being implemented, and what the main uncertainties are.
Predictive values
One important aspect in nationwide screening is the predic-
tive value of a positive screening mammogram. A relatively
low value (considering age group) will strongly increase the
workload for clinical medicine and may result in a less
favourable balance between positive and negative effects.
Our assumptions are based on results obtained in the
Dutch trials over 10 years. The predictive values of biopsies
(52% at first and 70% at subsequent screens) correspond well
with those of 50% and 75%, respectively, reported from
Kopparberg/Ostergotland. The policy not to take a biopsy of
mammographically benign lesions and the systematic consul-
tation between different specialists may contribute to these
good results. In some countries less favourable figures are
reported (Day & Miller, 1988).
The question remains whether good results from screening
projects will also be achieved in a national setting (Day et al.,
1989). Quality control will be an important part of the
programme in the Netherlands. Training of radiographers,
radiologists and pathologists before the implementation of
screening, and periodic evaluation ofdiagnostic and technical
performance will be tasks of a national reference centre.
Detecting more breast cancers and non-invasive cancers
Theoretically, overdiagnosis and subsequent overtreatment
are important risks involved in mass screening. In practice it
is difficult to assess whether overdiagnosis is actually taking
place. Screening always leads to a (temporary) increase in
the number of women with breast cancer, which is only a
desirable effect and should not be confused with overdiag-
nosis. After termination of the programme one would expect
a relative fall in this number.
Inevitably, some women will be detected who would, in the
absence of screening, have died from other causes before the
cancer had become manifest. However, this percentage is
rather small; we predicted an increase in the incidence of at
most 3% because of this phenomenon.
Overdiagnosis may also occur if some of the tumours
would, in the absence of screening, never have progressed, or
only very slowly, to a stage in which symptoms would lead to
a clinical diagnosis. This may apply to ductal carcinoma in
situ. In this analysis all screen-detected cancers are assumed
to be progressive.
The percentages of dCIS are very similar in the major
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detected cancers (Tabar et al., 1985; UK Trial, 1988; Anders-
son et al., 1988; Hendriks, 1982). In this respect our model
fits with international data. When starting nationwide screen-
ing, this type of cancer will still remain a small fraction of
the total number of diagnosed breast cancers. In view of
these modest percentages, it can be concluded that even if
some of these tumours would not progress or even regress, it
would only result in a very small amount of overdiagnosis.
For the women invited, the fact that non-invasive
carcinoma, until now treated by mastectomy, may be a non-
progressive lesion is of more (psychological) importance.
Knowledge that less radical treatment for early lesions is
advocated could have a positive effect on the attendance rate.
Detection rates and stage distribution
The predicted numbers of screen-detected and interval
cancers are based on assumptions on pre-clinical duration
and sensitivity, and are compatible with data from screening
projects in Nijmegen, Utrecht and New York. These data
were also found to correspond closely, adjusting for screen-
ing interval, with published data from the randomised
Kopparberg/Ostergotland trial (van der Maas et al., 1988).
Moreover, the distribution of tumour size and lymph node
metastases of the detected cancers influences the predictions
on assessment and treatment. The data on women with
clinically diagnosed breast cancer were comparable with data
from large non-screened patient groups.
In screen-detected cases, we expected 30% of the cancers
to be over 20 mm at the first screen, and 15% at subsequent
screens, which results in an average of 20% in the stable
period (Figure 2). Tabar reported 26% of the cancers to have
a diameter of 20 mm or more up to 1986 (Day et al., 1989).
Within each tumour size class, women with screen-detected
cancer had a lower percentage of axillary lymph node
metastases in the Kopparberg/Ostergotland trial, although
not statistically significant (Taber et al., 1987). However, the
same difference was found in the Dutch trials and is used in
the treatment predictions.
Impact on primary treatment
Publications on changes in treatment as a result of mass
screening are scarce (Andersson et al., 1988; Holmberg et al.,
1986). According to Andersson, no important differences
were found in the treatment of women with breast cancer
between study and control group of the Malm0 trial. How-
ever, Malm0 figures do show that less women were given
hormone therapy or chemotherapy in the study group. It is
unclear whether the therapy trial, which was operational, has
contributed to this difference.
More importantly, in the control group in Malm0 20% of
the women with breast cancer underwent breast preserving
therapy. In the study group, this figure was 25%, if including
stage 0 tumours, and 23% if not. This means a relative
increase of 15-25% compared to the control group. Because
of small numbers, the difference was not statistically
significant and did not seem important. But for a nationwide
programme this increase in breast conserving therapy by
15-25%, when compared to the situation without screening,
will have a major impact on health care facilities. The
Malm0 trial seems to support our 25% increase in this type
of treatment.
At least three important developments may influence the
predictions on treatment. The first is the tendency to apply
breast conserving therapy even in tumours over 3 cm
(van Dongen et al., 1987). Secondly, there is discussion wheth-
er radiotherapy may be omitted in some cases, e.g. in screen-
detected small or in situ lesions. Finally there is increasing
discussion about the benefit of adjuvant systemic treatment.
Assessment outside the screening programme
Our results show that centrally organised screening will result
in less biopsies than in the situation without screening. This
beneficial effect will depend to a large extent on the expected
change in the number of preventive mammograms after the
implementation.
Many women visit their doctor for breast problems now-
adays. Gravelle et al. (1982) found that 4.7% of women
above 40 years of age were examined at the hospital (or
undergoing a biopsy) because of breast symptoms or com-
plaints, but no cancer was found ('worried well').
In the Malm0 trial, the control group had free access to
mammography equipment outside the programme. Some
24% of women in the control group (age 45 and more) have
actually had a mammogram in a mean period of 8.8 years,
most only once (Andersson et al., 1988). A percentage of
13% over a period of at most 7 years is mentioned in the
Kopparberg/Ostergotland study (Tabar et al., 1985). These
figures are comparable with our estimate of 2% in the age
group over 40. However, it is difficult to predict the possible
decrease in preventive mammograms outside the programme,
when a national screening programme is being implemented.
Some 500,000 screening mammograms per year in the
Netherlands will certainly cause a strong decrease in mam-
mograms outside the programme in the age group 50-70.
However, it remains uncertain how much the demand for
women in other age groups will increase at the same time.
Overview
The increase in referrals and women diagnosed as having
breast cancer will have its impact on workload in the first
years of screening. Breast conserving therapy requires more
time and effort from surgical and radiotherapy departments,
and assessment of non-palpable lesions with specimen radio-
graphy and paraffin section increases the workload for
pathologists. The decrease in women with advanced disease
will have the opposite effect on workload only after several
years. It was outside the scope of the present study to make a
detailed analysis of the treatment of advanced disease.
Uncertainties remain about the attitude of women towards
breast assessment outside a screening programme, and about
the development of breast conserving therapy in the future.
In overview, the favourable effects of nationwide breast
cancer screening outweigh the unfavourable effects. To be
able to ensure these advantages, assessment and treatment
should also be monitored and evaluated in a national system.
The present results may enable a more balanced judgement
to be made on the value of breast cancer screening and its
impact on clinical medicine.
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